Evusheld Patient Information

Updated 25th Aug 2022

Download button - information sheet

Patient information on Evusheld (tixagevimab and cilgavimab)

As your health care providers, all members of the Australian Rheumatology Association (ARA), (rheumatologists, nurses, physiotherapists, exercise physiologists and other allied health providers), are keen to provide you with information about COVID-19. For specific questions please contact your rheumatology team.

We will aim to provide updates as new information becomes available.

What is Evusheld?

  • Evusheld is a medicine containing two active ingredients: tixagevimab and cilgavimab. 
  • Evusheld is given by a healthcare provider as two intramuscular injections, one into each buttock, you will receive 2 injections, one after the other at the same visit. 
  • Evusheld helps to prevent people from getting COVID-19 and can give someone 6 months of extra protection against COVID-19.
  • Evusheld is not recommended as a substitute for COVID-19 vaccination. 

  • Evusheld is used to:
    • prevent COVID-19 infection
    • treat COVID-19 infection (at the time of writing, only applicable for NSW and QLD). In some states (i.e. NSW and QLD), Evusheld is recommended by the Department of Health for the treatment of non-hospitalised patients with mild-moderate COVID-19 within 5 days of symptom onset.

How does Evusheld work and who is eligible to receive it?

  • Evusheld is an antibody that works against the COVID-19 virus, stopping it from entering cells and therefore preventing people from getting COVID-19.
  • Evusheld has been approved by the Australian government for the prevention of COVID-19 in adults and adolescents (≥ 12 years and ≥ 40 kg) who have not been recently in contact with someone who has COVID-19 if they: 
    • have an illness or are taking medicines such as certain immunosuppressants or high dose corticosteroids) which make them unlikely to respond to or be protected by vaccination against COVID-19, or
    • are not recommended to have a COVID-19 vaccine due to a history of severe adverse reaction (for example, severe allergic reaction) to a COVID 19 vaccine(s) and/or COVID‐19 vaccine component(s).
  • Evusheld is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended.

Who should check with their doctor before starting Evusheld?

Before you have Evusheld, please discuss further with your healthcare professional if you:
  • have had a heart attack or stroke, or other heart conditions, which put you at higher risk of having cardiac (heart) events
  • have a bleeding disorder, low numbers of blood platelets or are taking a blood-thinning medicine (to prevent blood clots)
  • are taking any medicines or have any allergies to any of the ingredients in the medicine
  • are pregnant, breastfeeding or are planning to have a baby soon
  • have recently received a COVID-19 vaccine within 2 weeks or had a confirmed COVID-19 infection within 4 weeks. It is possible that Evusheld may reduce your body’s immune response to a COVID-19 vaccine.

What else should I know while I am being given Evusheld?

Serious side effects are uncommon with Evusheld, and you may not get any side effects when receiving Evusheld. Common side effects include:
  • headache
  • fatigue (tiredness)
  • pain, redness, itching or rash at the injection site.
Tell your healthcare professional straight away if you notice any signs of rare but serious allergic reaction, such as:
  • difficulty breathing or swallowing
  • swelling of the face, lips, tongue or throat
  • severe itching of the skin, with a red rash or raised bumps.
More information can be found on the Consumer Medicine Information (CMI) leaflet

How can I obtain Evusheld?

  • Evusheld is a prescription only medicine, so it is only available with a prescription from an authorised prescriber. For more information, please contact your rheumatologist or other health care provider.
  • There are currently limited supplies of Evusheld in Australia. These supplies are being provided by the Australian Government to all State and Territory governments through the National Medical Stockpile. 
  • To access supplies of Evusheld, healthcare professionals will need to contact their relevant State or Territory Health departments as there are different processes and eligibility depending on each State and Territory.
  • For more information, please contact your local State and Territory Health Departments
    • NSW
    • QLD
    • SA
    • VIC
    • WA
    • ACT,NT, TAS - there are currently no guidelines available online. Speak to your rheumatologist to find out whether this medicine is suitable for you.